Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Agreement of clinicians’ assessment of FN risk category with EORTC recommendations for CT regimens (N = 1174)

From: Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

FN risk category of CT regimen assessed by clinician Patients in FN risk category assessed according to recommendations, n (%)
< 10% (n = 56) 10–20% (n = 513) ≥ 20% (n = 65) Unknown (n = 540)
< 10% 2 (3.6) 63 (12.3) 4 (6.2) 58 (10.7)
10–20% (with patient risk factors) 36 (64.3) 258 (50.3) 19 (29.2) 299 (55.4)
≥ 20% 18 (32.1) 192 (37.4) 42 (64.6) 183 (33.9)
  1. Bold numbers indicate patients where the clinicians’ assessment of FN risk category agrees with the EORTC-recommended FN risk category
  2. CT chemotherapy, EORTC European Organisation for Research and Treatment of Cancer, FN febrile neutropenia